Targovax to present at the upcoming 2020 Virtual European Biotech Investor Day 2020
Oslo, Norway, 22 June, 2020 – Targovax ASA, a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today announces that Magnus Jäderberg, Chief Medical Officer of Targovax, will present an overview of the company at the upcoming Virtual European Biotech Investor Day 2020 hosted by Solebury Trout, Goodwin, Deutsche Bank and Nasdaq. Participants will be able to submit questions electronically during the presentation, with answers provided at